HC Wainwright Issues Optimistic Outlook for NMRA Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Investment analysts at HC Wainwright upped their Q2 2025 EPS estimates for Neumora Therapeutics in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.42) per share for the quarter, up from their prior forecast of ($0.43). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($1.68) EPS, FY2027 earnings at ($1.84) EPS, FY2028 earnings at ($1.51) EPS and FY2029 earnings at ($0.20) EPS.

A number of other equities research analysts have also recently commented on NMRA. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 target price on shares of Neumora Therapeutics in a research report on Tuesday. William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a research report on Wednesday, January 15th. Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday. Finally, Bank of America cut their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

Neumora Therapeutics Stock Up 1.4 %

Shares of NASDAQ NMRA opened at $1.43 on Thursday. The firm has a 50-day simple moving average of $2.83 and a 200-day simple moving average of $8.76. The stock has a market capitalization of $231.03 million, a price-to-earnings ratio of -0.76 and a beta of 2.59. Neumora Therapeutics has a 52 week low of $1.35 and a 52 week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Neumora Therapeutics during the fourth quarter valued at about $61,000. PNC Financial Services Group Inc. acquired a new stake in shares of Neumora Therapeutics during the fourth quarter valued at about $64,000. Quantbot Technologies LP acquired a new stake in shares of Neumora Therapeutics during the fourth quarter valued at about $92,000. PEAK6 LLC acquired a new stake in shares of Neumora Therapeutics during the fourth quarter valued at about $117,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Neumora Therapeutics during the fourth quarter valued at about $135,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.